Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMP1 | P13497 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KCNT1 | Q5JUK3 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5394161 | 0.86 | TDP1 (0.36) | ALDH1A1RAB9ALMNATSHRNPC1 | |
| SCHEMBL5398704 | 0.86 | ALDH1A1 (0.37) | ALDH1A1NPSR1LMNATSHR | |
| SCHEMBL5396647 | 0.84 | HDAC6 (0.39) | BMP1TSHR | |
| SCHEMBL5397582 | 0.83 | — | — | |
| SCHEMBL5395569 | 0.82 | — | — | |
| SCHEMBL5384676 | 0.74 | ALDH1A1 (0.39) | BMP1POLBALDH1A1RAB9ANPSR1 | |
| SCHEMBL5385731 | 0.74 | CYP2D6 (0.33) | ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL5384543 | 0.73 | SMN1; SMN2 (0.41) | POLBRAB9ASMN1; SMN2LMNANPC1 | |
| SCHEMBL3871936 | 0.69 | CNR2 (0.33) | ALDH1A1RAB9A | |
| SCHEMBL5426321 | 0.68 | REN (0.41) | NPSR1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070203138-A1 | Novel Compounds and Compositions as Cathepsin S Inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-08-30 | — | — | US | claimed |
| US-7226921-B2 | Compounds and compositions as cathepsin S inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-05 | — | — | US | claimed |
| US-6977256-B2 | Compounds and compositions as cathepsin S inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-20 | — | — | US | claimed |
| US-20050267044-A1 | Novel compounds and compositions as cathepsin S inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-01 | — | — | US | claimed |
| EP-1446392-A1 | OLIGOPEPTIDES AND COMPOSITIONS CONTAINING THEM AS CATHEPSIN S INHIBITORS | Aventis Pharmaceuticals, Inc. (US) | 2004-08-18 | — | — | EP | claimed |
| US-20030199506-A1 | Novel compounds and compositions as cathepsin S inhibitors | AXYS PHARMACEUTICALS INC. | 2003-10-23 | — | — | US | claimed |
| WO-2003042197-A1 | OLIGOPEPTIDES AND COMPOSITIONS CONTAINING THEM AS CATHEPSIN S INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2003-05-22 | — | — | WO | claimed |
| US-20070203138-A1 | Novel Compounds and Compositions as Cathepsin S Inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-08-30 | — | — | US | disclosed |
| US-7226921-B2 | Compounds and compositions as cathepsin S inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-6977256-B2 | Compounds and compositions as cathepsin S inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-20 | — | — | US | disclosed |
| US-20050267044-A1 | Novel compounds and compositions as cathepsin S inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-01 | — | — | US | disclosed |
| EP-1446392-A1 | OLIGOPEPTIDES AND COMPOSITIONS CONTAINING THEM AS CATHEPSIN S INHIBITORS | Aventis Pharmaceuticals, Inc. (US) | 2004-08-18 | — | — | EP | disclosed |
| US-20030199506-A1 | Novel compounds and compositions as cathepsin S inhibitors | AXYS PHARMACEUTICALS INC. | 2003-10-23 | — | — | US | disclosed |
| WO-2003042197-A1 | OLIGOPEPTIDES AND COMPOSITIONS CONTAINING THEM AS CATHEPSIN S INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267044-A1 | Novel compounds and compositions as cathepsin S inhibitors | CTSS, CTSB, CTSE | BMP1 2923/4885POLB 2078/4885ALDH1A1 4037/4885 |
| US-20070203138-A1 | Novel Compounds and Compositions as Cathepsin S Inhibitors | CTSS, CTSB, CTSE | BMP1 2923/4885POLB 2078/4885ALDH1A1 4037/4885 |
| US-20030199506-A1 | Novel compounds and compositions as cathepsin S inhibitors | CTSS, CTSB, CTSE | BMP1 2224/4885POLB 1980/4885ALDH1A1 3353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.